<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02139826</url>
  </required_header>
  <id_info>
    <org_study_id>IX-0102</org_study_id>
    <nct_id>NCT02139826</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability and Food Effect Study of IX-01 Capsules in Healthy Men</brief_title>
  <official_title>A Randomised, Single-dose, 3-way Crossover Study to Evaluate the Relative Bioavailability of the IX-01 Capsule Formulation Compared With the IX-01 Aqueous Dispersion Formulation, and the Effect of Food on the IX-01 Capsule Formulation, in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ixchelsis Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ixchelsis Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the absorption and blood levels of IX-01 when given
      as a capsule compared to liquid form, and how food affects the absorption in healthy men.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative Bioavailability (Frel) of a Capsule compared to a Liquid Formulation of IX-01 while Fasting, as Calculated by a Ratio of Area Under the Plasma Concentration Time Curve from Time 0 to Infinity</measure>
    <time_frame>Pre-dose up to 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative Bioavailability (Frel) of a Capsule Formulation of IX-01 in the Fasted State compared to the Fed State, as Calculated by a Ratio of Area Under the Plasma Concentration Time Curve from Time 0 to Infinity</measure>
    <time_frame>Pre-dose up to 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative Bioavailability (Frel) of a Capsule compared with a Liquid Formulation of IX-01 while Fasting, as calculated by a Ratio of Peak Plasma Concentrations</measure>
    <time_frame>Pre-dose up to 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative Bioavailability (Frel) of a Capsule Formulation of IX-01 in a Fasted State compared to a Fed State, as calculated by a Ratio of Peak Plasma Concentrations</measure>
    <time_frame>Pre-dose up to 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve from Time 0 to Infinity, Following a Single Dose of IX-01</measure>
    <time_frame>Pre-dose and up to 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of IX-01</measure>
    <time_frame>Pre-dose and up to 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Peak Plasma Concentration (Tmax) of IX-01</measure>
    <time_frame>Pre-dose up to 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Half Life (t1/2) of IX-01</measure>
    <time_frame>Pre-dose up to 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Rate Constant (Kel) of IX-01</measure>
    <time_frame>Pre-dose up to 96 hours post last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve From Time 0 to the Time of the Last Measurable Sample of IX-01</measure>
    <time_frame>Pre-dose to the time of the last measurable sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of IX-01 in Cerebrospinal Fluid (CSF) after a Single Dose of the Liquid Formulation of IX-01</measure>
    <time_frame>1, 2, 4 and 6 hours after dosing</time_frame>
    <description>Listed by time point of 1, 2, 4, 6 hours post dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with One or More Drug-Related Adverse Events (AEs) or any Serious AEs</measure>
    <time_frame>Baseline to study completion (approximately 6 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>IX-01 Capsule while Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IX-01 Aqueous Dispersion while Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 800 milligrams IX-01 as an aqueous dispersion, while fasting in 1 of 3 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IX-01 Capsule after Food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IX-01</intervention_name>
    <arm_group_label>IX-01 Capsule while Fasting</arm_group_label>
    <arm_group_label>IX-01 Aqueous Dispersion while Fasting</arm_group_label>
    <arm_group_label>IX-01 Capsule after Food</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A body mass index (Quetelet index) in the range 18-30 kilograms/meters squared (kg/m2)

          -  Body Mass Index = weight [kg] divided by (height [m])2

          -  Total body weight greater than (&gt;)50 kg at screening

          -  Ability to communicate satisfactorily with the investigator and to participate in, and
             comply with the requirements of, the entire trial

          -  Participants and their partners must be willing to use adequate forms of contraception
             and to comply with the contraception requirements during the trial and for 4 months
             after the last dose of medication

          -  Willingness to give written consent to have data entered into The Over Volunteering
             Prevention System

        Exclusion Criteria:

          -  Clinically relevant abnormal history, physical findings, ECG, or laboratory values at
             the pre-trial screening assessment, including:

               -  Lipid and/or liver function test results &gt;1.25 x Upper Limit of Normal (ULN) or
                  other clinical laboratory blood biochemistry test results outside the normal
                  reference range unless discussed and approved by sponsor

               -  International normalised ratio (INR) of &gt;1.2 or a platelet count &lt; 150 x
                  109/Liter

               -  History of unexplained syncope

               -  Family history of unexplained sudden death, or sudden death due to long QT
                  syndrome

               -  Fridericia Correction Formula (QTcF) interval &gt;450 milliseconds (msec) at
                  screening

               -  Bundle branch block and other conduction abnormalities, other than mild first
                  degree atrio-ventricular block

               -  Irregular rhythms other than sinus arrhythmia or occasional supraventricular
                  ectopic beats

               -  T-wave configuration of insufficient quality for determination of QT interval, as
                  assessed by the investigator

          -  Presence of acute or chronic illness or history of chronic illness sufficient to
             invalidate participation in the trial

          -  Impaired gastrointestinal, endocrine, thyroid, hepatic, cardiovascular, respiratory,
             haematological, renal or neurological function, diabetes mellitus, coronary heart
             disease, or history of any psychotic mental illness

          -  Surgery (for example (e.g.) stomach bypass) or medical condition that might affect
             absorption, metabolism or elimination of medicines

          -  Any skin condition, abnormality of the lumbar spine, medical or surgical condition
             that would preclude lumbar puncture (e.g. coagulopathy, local or systemic infection,
             left ventricular outflow obstruction, aortic stenosis, previous back surgery)

          -  Presence or history of severe adverse reaction to any drug

          -  Use of any prescription or over-the-counter medicine during the 14 days before the
             first dose of trial medication, or intention to use any medicine during the trial,
             with the exception of short courses of medication considered by the investigator not
             to interfere with the safety of the participant or the integrity of the trial data
             (such as acetaminophen (paracetamol))

          -  Current use of any herbal remedy or nutritional supplement, or intention to use any
             such product during the study

          -  Participation in another clinical trial of a new chemical entity or a prescription
             medicine within the previous 3 months.

          -  Previous participation in this trial or any other clinical trial of an oxytocin
             receptor antagonist

          -  Presence or history of drug or alcohol abuse, or intake of more than 21 units of
             alcohol weekly or more than 5 cigarettes daily

          -  Blood pressure and heart rate in supine position at the screening examination outside
             the ranges 100-130 millimeters of mercury (mm Hg) systolic, 60-90 mm Hg diastolic;
             heart rate 50-100 beats/minute. Measurements must be made in duplicate, and all values
             must fall within the acceptable ranges

          -  Possibility that the participant will not cooperate with the requirements of the
             protocol

          -  Evidence of drug abuse on urine testing

          -  Positive test for hepatitis B, hepatitis C, Human Immunodeficiency Virus 1 (HIV1) or
             Human Immunodeficiency Virus 2 (HIV2)

          -  Loss of more than 400 mL blood during the 3 months before the trial, e.g. as a blood
             donor

          -  Objection by General Practitioner (GP), on medical grounds, to participant entering
             trial

          -  Employee of the investigator site or any company involved in sponsoring, organizing or
             conducting the trial, or immediate family of the employee
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email: Ixchelsis@Choruspharma.com</last_name>
    <role>Study Director</role>
    <affiliation>Ixchelsis Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Medicines Research</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2014</study_first_submitted>
  <study_first_submitted_qc>May 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2014</study_first_posted>
  <last_update_submitted>December 16, 2014</last_update_submitted>
  <last_update_submitted_qc>December 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

